PD-1/PD-L1 inhibitor 1 BMS-1
- 公司名稱 MedChemExpress LLC
- 品牌 MedChemExpress (MCE)
- 型號 PD-1/PD-L1 inhibitor 1
- 產(chǎn)地
- 廠商性質(zhì) 生產(chǎn)廠家
- 更新時(shí)間 2019/7/11 18:06:54
- 訪問次數(shù) 688
聯(lián)系我們時(shí)請說明是化工儀器網(wǎng)上看到的信息,謝謝!
供貨周期 | 現(xiàn)貨 | 規(guī)格 | 10 mM * 1 mL;5 mg;10 mg |
---|---|---|---|
貨號 | HY-19991 | 應(yīng)用領(lǐng)域 | 生物產(chǎn)業(yè) |
BMS-1
產(chǎn)品活性:BMS-1 是 PD-1/PD-L1 蛋白質(zhì)/蛋白質(zhì)相互作用的抑制劑,IC50 為 6 到 100 nM。
研究領(lǐng)域:Immunology/Inflammation
作用靶點(diǎn):PD-1/PD-L1
In Vitro: Since PD-1 mediated the exhaustion of natural killer (NK) cell by binding to its ligand PD-L1, BMS-1 (PD-1/PD-L1 inhibitor 1) (1 μM, 3 days) is used to disturb the interaction between PD-1 and PD-L1. Dexamethasone induced increase of PD-1 expression and decrease of cytotoxicity of the co-cultured NK92 cells are reversed by BMS-1. BMS-1, a small-molecule immune checkpoint inhibitor of PD-1/PD-L1, can be used as a therapeutic strategy for tumor immunotherapy.
相關(guān)產(chǎn)品:Peptidomimetic Library | Anti-Cancer Compound Library | Small Molecule Immuno-Oncology Compound Library | Bioactive Compound Library Plus | Immunology/Inflammation Compound Library | BMS-202 | Atezolizumab | Nivolumab | PD-1-IN-1 | Pembrolizumab | Avelumab | BMS-1166 | Sulfamethizole | Sulfamethoxypyridazine | PD-1-IN-17 | PD-1-IN-18